Aescap logo

Investing in People and Medicine that Make a Difference

Investing in Medicine

Aescap 2.0 invests in high-growth public companies that develop and market highly innovative medicines.


Our net performance since inception on March 28 2016 is +135,5%, which is 2,7x that of the Nasdaq Biotech Index.

Get in Touch

The next information meeting will be held on March 10 in Amsterdam. In these meetings the biotech market, our investment philosophy, as well as methodology are discussed in an interactive setting.


Our investment decisions are based on thorough research and fundamental analyses. In the biotech sector such an analysis especially encompasses product portfolio patent protection, product development risks, market entry barriers, competition and the expected market development.

But equally important are the serious efforts we undertake to understand the strengths and weaknesses of a company’s management, team dynamics, and their view on the future of the company and the markets they serve.

Aescap Team

Patrick Krol, Portfolio Manager

Patrick joined Aescap at its start in 2005. Where Aescap initially invested in private life sciences companies, Patrick has been a private investor in public equity for over 30 years. His track record as a private investor in public biotech companies over the 2-year run-in period before starting Aescap 2.0 in 2016 is 133% (cumulative over 2014+2015), outperforming the Nasdaq Biotech Index over 2,5x. From 1995 to 2004 Patrick was the managing director of Firm United Healthcare B.V., a company that provided market research, strategy and communication consultancy services. As a co-founder of Firm United Healthcare Patrick was responsible for growing the company into a market leader on the European continent and guided over 35 listed pharma and biotech companies to successfully introduce or grow their products.

Maurits Brandt, Lead Analyst

Maurits Brandt holds a Master’s in Life Science and Business Development from Leiden University and a Bachelor’s in Biochemistry from Leiden University and TU Delft. During his master he specialized in the field of medical oncology and focused on the business aspects of exploiting emerging technologies. He performed his research on the Technische Universität Berlin. During this time, he started to learn about the aspects of long term investing in life sciences companies. Maurits joined Aescap 2.0 as an analyst in 2016.

Paolo del Bufalo, Analyst

Paolo Del Bufalo obtained a Bachelor’s degree in Chemistry at La Sapienza University of Rome after which he completed two Master tracks at Leiden University, one in Chemical Biology Research and one in Science Based Business. Throughout his academic research career he focused on supramolecular chemistry and photochemistry for applications in medicinal chemistry. During his business studies, he acquired knowledge to combine his scientific background with the business environment, particularly with value investing. Paolo joined Aescap 2.0 as an analyst in 2018.

Tristan Maguet, Analyst

Tristan Maguet holds a Pharm.D from the University of Grenoble Alpes and a MSc in Management from ESSEC Business School in Paris. During his pharmaceutical studies, Tristan specialized in the biotechnology industry and led a project where he went through all stages of development and registration for human growth hormone. Tristan developed his knowledge in the healthcare industry during his internships at Aescap 2.0 as an analyst and at venture capital fund Andera Partners in their BioDiscovery franchise as a biotech and medtech analyst. Tristan joined Aescap 2.0 as an analyst in 2019.

Claudine (Clo) Calame, Investor Relations

Claudine (Clo) Calame joined Aescap in 2019 to take care of investor relations. Clo started her career at KBC Bank before she moved to the pharmaceutical industry in 2000. Clo worked respectively for Merck, Pfizer, Roche and Sanofi Genzyme in various commercial positions, including market introduction whilst registration was still pending. Her field of expertise is immunology, especially Rheumatoid Arthritis and Multiple Sclerosis. Clo holds a Bachelor’s in Commercial Economics from the HES in Rotterdam.

Michiel de Haan (1947), Fund Advisor

Michiel de Haan has been active in life sciences since 1987 when he spun-out Atlas Venture from the ING bank. Under his leadership Atlas developed into a European-American venture capital firm with offices in Amsterdam, Munich, Boston and London and invested in over 300 venture backed companies in Information Technology and Life Sciences. Michiel has been active on numerous boards of Life Science companies such as Crucell and Morphosys.

Bo Jesper Hansen (1958), Portfolio Advisor

Bo Jesper Hansen, M.D., Ph.D. resigned as the Executive Chairman of the Board of SOBI AB (Swedish Orphan Biovitrum AB) in 2016. SOBI is a biotech company listed on the Swedish stock exchange and at the time had a market capitalization of around 3,5 billion euros. He is Chairman of Karolinska Development AB and is also non-executive Director of the biotech / pharma companies Ablynx NV, Orphazyme ApS, Newron Pharmaceuticals SpA, CMC AB and Genspera Inc. Dr Hansen served as CEO and President to the Board of Swedish Orphan International (1998-2010) until the merger with Biovitrum, forming Swedish Orphan Biovitrum. He then became the company’s executive chairman. He also was non-executive Director of Gambro until its acquisition by Baxter, as well as of Zymenex, until its acquisition by Chiesi.

Fred Oudshoorn (1950), Portfolio Advisor

Fred Oudshoorn is the founder and managing director of Jonghoud BV, an investment firm in amongst others, equity of private and listed healthcare companies. As a pharmacist he built a chain of 40 pharmacies “De Vier Vijzels” which was later acquired by Alliance Unichem. He is also a founder of MediZorg, the former chairman of Sinensis Laboratoria and supervisory board member of Kadans and Kadans Science Partners. Mr Krol and Mr Oudshoorn first met in their function as supervisory board members back in 2012 and soon discovered their mutual activities in investing in public innovative medical companies.

Gert Hoogland

Gert Hoogland, M.D., MBA (INSEAD) is a pharmaceutical executive with deep operational experience. He began his career in 1982 as Medical Advisor to Organon NV in Oss, The Netherlands, followed by CEO positions for Schering AG in New Zealand and South Africa. He then founded Pharmaplan Pty Ltd in Johannesburg, which became the leading specialty pharma distributor in Africa representing biotech companies like Biogen, Bracco, Recordati, Ipsen, Genzyme and Shire. After the sale of this company to the Canadian Specialty Pharma company Paladin Inc., he relocated to Zurich to start HealthCrest AG, a healthcare investment and consulting company.

5-star Morningstar rating

Morningstar has rated Aescap 2.0 as a 5-star investment fund, the highest possible rating given. Morningstar’s rating has become the industry’s leading standard for determining a fund’s performance (risk/reward) relative to other funds. To rate a fund, Morningstar takes into account the long-term performance (3+ years) and only the top 10% best performing funds will receive a 5-star rating.

See Aescap on Morningstar


Monthly Update January

January was a rollercoaster month for the fund. During the month the fund peaked at more than +4%, but ended at -4.6%. It is probably needless to say that the general market conditions, due to the fear for the economic effect of the coronavirus, was the cause of downturn. Despite a healthy level of alertness by the WHO towards the virus is justified, we do not see these developments as a threat to the biotech industry.

Read more
Quarterly Report Q4, 2019

After a sluggish third quarter we had a very positive fourth quarter in which the fund made a net performance of +24.6%. We ended 2019 with a net performance of +29.98%. This resulted in a 2.9x (188%) net outperformance of the NASDAQ Biotech Index (NBI) since our inception. During the fourth quarter the share price of several portfolio companies came close to our price targets, leading to a sale of those positions. At the same time, new undervalued high-growth companies were added to the portfolio.

Read more
Monthly Update November

November was again a good month for the fund with a net performance of +11,1%, bringing the fund’s performance for 2019 to +23,3%.

Read more